검색어 : 통합검색[351.7]
총 2,653건 중 1,000건 출력
, 6/100 페이지
-
51
- Young, M.J.L., 'Catalogue of oriental manuscripts. VII. Arabic mss. 351-371, Turkish mss. 1-7' (Book Review)
- BOSWORTH, C. E.; ; (Journal of Semitic studies, v.26, 1981, pp.141-141)
-
52
- REVIEWS Les Journaux Intimes. By LELEUMICHÈLE. (Caractères, 7). Paris: Presses Universitaires de France. 1952. xi + 351 pp. 1000 francs.
- JONES, P. MANSELL; MANCHESTER; (French studies, v.8, 1954, pp.82-84)
-
53
- The Tweed Ring. By <i>Alexander B. Callow, Jr.</i> (New York: Oxford University Press. 1966. Pp. xi, 351. $7.00.)
- Mandelbaum, Seymour J.; University of Pennsylvania; (The American historical review, v.72, 1967, pp.1105-1105)
-
54
- 2005/C 296/66 Case T-351/05: Action brought on 7 September 2005 - Provincia di Imperia v Commission
- ; ; (Official journal of the European Union. Information and notices, v.48, 2005, pp.30)
-
55
- Joseph lister 1827-1912. Richard B. Fisher. 232 × 155 mm. Pp. 351. 1977. London: Machdonald × Jane's. £7·95
- Dudley, H A F; ; (British journal of surgery : BJS, v.65, 1978, pp.66-66)
-
56
- AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
- Shimony, Shai O.; Murdock, Heardley; Keating, Julia; Reilly, Christopher R.; Tsai, Harrison K.; Gibson, Christopher J.; Faderl, Stefan; Wagner, Tony; Dronamraju, Nalina; Lin, Tara L.; Ritchie, Ellen K.; Prebet, Thomas; Cortes, Jorge E.; Uy, Geoffrey L.; Lancet, Jeffrey E; Neuberg, Donna S.; Stone, Richard M.; Lindsley, R. Coleman; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 3Department of Pathology, Brigham and Women's Hospital, Boston, MA; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; 6Jazz Pharmaceuticals, Palo Alto, CA; 6Jazz Pharmaceuticals, Palo Alto, CA; 6Jazz Pharmaceuticals, Palo Alto, CA; 7Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS; 8Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY; 9Bristol Myers Squibb, Princeton, NJ; 10Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA; 11Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis,; (Blood, v.144, 2024, pp.60-60)
-
57
- Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
- Munster Vincent; Flagg Meaghan; Singh Manmeet; Williamson Brandi; Feldmann Friederike; Perez-Perez Lizzette; Brumbaugh Beniah; Holbrook Myndi; Adney Danielle; Okumura Atsushi; Hanley Patrick; Smith Brian; Lovaglio Jamie; Anzick Sarah; Martens Craig; van Doremalen Neeltje; Saturday Greg; de Wit Emmie; ; (, v., 2021, )
-
58
- Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study
- Louis, Guillaume; Belveyre, Thibaut; Goetz, Christophe; Gibot, Sé bastien; Dunand, Paul; Conrad, Marie; Gaci, Rostane; Gette, Sé bastien; Ouamara, Nadia; Perez, Pascale; Cadoz, Cyril; Picard, Yoann; Mellati, Nouchan; Intensive Care Unit, Metz-Thionville Regional Hospital, Mercy Hospital , Metz , France; Department of Anesthesiology and Intensive Care Medicine, University Hospital of Nancy , Vandoeuvre-Lè s-Nancy , France; Clinical Research Support Unit, Metz-Thionville Regional Hospital, Mercy Hospital , Metz , France; Medical Intensive Care Unit, University Hospital of Nancy , Nancy , France; Intensive Care Unit, Metz-Thionville Regional Hospital, Bel Air Hospital , Thionville , France; Medical Intensive Care Unit, University Hospital of Nancy , Nancy , France; Intensive Care Unit, Metz-Thionville Regional Hospital, Mercy Hospital , Metz , France; Intensive Care Unit, Metz-Thionville Regional Hospital, Mercy Hospital , Metz , France; Clinical Research Support Unit, Metz-T; (Frontiers in medicine, v.9, 2022, pp.828402)
-
59
- Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML
- Uy, Geoffrey L.; Newell, Laura F.; Lin, Tara L.; Goldberg, Stuart L.; Wieduwilt, Matthew J.; Ryan, Robert J.; Faderl, Stefan; Lancet, Jeffrey E.; Division of Oncology, Washington University School of Medicine, St. Louis, MO; ; Knight Cancer Institute, Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR; ; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; ; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; ; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK; ; Department of Biostatistics, Jazz Pharmaceuticals, Philadelphia, PA; ; Department of Clinical Development, Jazz Pharmaceuticals, Palo Alto, CA; and; Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; (Blood advances, v.6, 2022, pp.4989-4993)
-
60
- Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies
- Cerutti Gabriele; Rapp Micah; Guo Yicheng; Bahna Fabiana; Bimela Jude; Reddem Eswar R; Yu Jian; Wang Pengfei; Liu Lihong; Huang Yaoxing; Ho David D; Kwong Peter D; Sheng Zizhang; Shapiro Lawrence; ; (, v., 2021, )
QUICK MENU
